Translational studies of glutathione in bladder cancer cell lines and human specimens

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 793-798

  Pendyala, Lakshmi ^a   Velagapudi, Satish ^a   Toth, Karoly ^a   Zdanowicz, Joseph ^a   Glaves, Dorothy ^a   Slocum, Harry ^a   Perez, Raymond ^a   Huben, Robert ^a   Creaven, Patrick J ^a   Raghavan, Derek ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; GENE EXPRESSION; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR;

BRAIN NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; FEMALE; GLIOBLASTOMA; GLUTATHIONE; HUMANS; MELANOMA; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0030921001     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bosl, G. J., Fair, W. R., Herr, H. W., Bajorin, D. F., Dalbagni, G., Sarkis, A. S., Reuter, V. E., Cordoncardo, C., Sheinfeld, J., and Scher, H. I. Bladder cancer: advances in biology and treatment. Crit. Rev. Oncol. Hematol., 16: 33-70, 1994.
2. Schroder, C. P., Godwin, A. K., O'Dwyer, P. J., Tew, K. D., Hamilton, T. C., and Ozols, R. F. Glutathione and drug resistance. Cancer Invest., 14: 158-168, 1996.
3. Mulders, T. M. T., Keizer, H. J., Breimer, D. D., and Mulder, G. J. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients. Drug Metab. Rev., 27: 191-229, 1995.
4. Perez, R. P., Hamilton, T. C., Ozols, R. F., and Young, R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Phila.), 71: 1571-1580, 1993.
5. Perez, R. P., Hamilton, T. C., and Ozols, R. F. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol. & Ther., 48: 19-27, 1990.
6. Moscow, J. A., and Dixon, K. H. Glutathione-related enzymes, glutathione, and multidrug resistance. Cytotechnology, 12: 155-170, 1993.
7. Mistry, P., and Harrap, K. R. Historical aspects of glutathione and cancer chemotherapy. Pharmacol. & Ther., 49: 125-132, 1991.
8. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin Oncol 12: 194-205, 1994.
9. O'Dwyer, P. J., Hamilton, T. C., Young, R. C., Lacreta, F. P., Carp, N., Tew, K. D., Padavic, R., Comis, R. L., and Ozols, R. F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J. Natl. Cancer Inst., 84: 264-267, 1992.
10. Wong, D. Y-K., Hsiao, Y-L., Poon, C-K., Kwan, P-C., Chao, S-Y., Chou, S-T., and Yang, C-S. Glutathione concentration in oral cancer tissues. Cancer Lett., 81: 111-116, 1994.
11. Chang, T. C., Chang, M. J., and Hsueh, S. Glutathione concentration and distribution in cervical cancers and adjacent normal tissue. Gynecol. Obstet. Invest., 36: 52-55, 1993.
12. Perry, R. R., Mazetta, J., Levin, M., and Barranco, S. Glutathione levels and variability in breast tumors and normal tissue. Cancer (Phila.), 72: 783-787, 1993.
13. El-Sharabasy, M. M. H., El-Dosoky, I., Horria, H., and Khalaf, A. H. Elevation of glutathione, glutathione-reductase, and nucleic acids in both normal tissues and tumor of breast cancer patients. Cancer Lett 72: 11-15, 1993.
14. Giralt, M., Lafuente, A., Pujol, F., and Mallol, J. Enhanced glutathione S-transferase activity and glutathione content in human bladder cancer. Follow-up study: influence of smoking. J Urol 149: 1452-1454, 1993.
15. Lafuente, A., Giralt, M., Cervello, I., Pujol, F., and Mallol, J. Glutathione S-transferase activity in human superficial transitional cell carcinoma of the bladder. Comparison with healthy controls. Cancer (Phila.), 65: 2064-2068, 1990.
16. Singh, S. V., Xu, B. H., Tkalcevic, G. T., Gupta, V., Roberts, B., and Ruiz, P. Glutathione-linked detoxification pathway in normal and malignant human bladder tissue. Cancer Lett., 77: 15-24, 1994.
17. Raghavan, D., Russell, P. J., and Brown, J. L. Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. Semin Surg. Oncol., 8: 279-284, 1992.
18. Russell, P. J., Jelbart, M., Wills, E., Singh, S., Wass, J., Wotherspoon, J., and Raghavan, D. Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int. J. Cancer 41: 74-82, 1988.
19. Russell, P. J., Wass, J., Lukeis, R., Garson, M., Jelbart, M., Wills, E., Philips, J., Brown, J., Carrington, N., Vincent, P. C., and Raghavan, D. Characterization of cell lines derived from mutually aneuploid human bladder transitional cell carcinoma, UCRU-BL-13. Int. J. Cancer, 44: 276-285, 1989.
20. Fahey, R. C., and Newton, G. L. Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Methods Enzymol., 143: 85-96, 1987.
21. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 113: 548-555, 1985.
22. Lowry, O. H., Rosenbrough, M. T., Farr, A. L., and Randall, R. J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
23. Deleve, L. D., and Kaplowitz, N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol. & Ther., 52: 287-305, 1991.
24. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89: 3070-3074, 1992.
25. Russell, P. J., Raghavan, D., Gregory, P., Philips, J., Wills, E. J., Jelbart, M., Wass, J., Zbroja, R. A., and Vincent, P. C. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res., 46: 2035-2040, 1986.
26. Kosower, E. M. The glutathione status of cells. Int. Rev. Cytol., 54: 109-160, 1978.
27. El-akawi, Z., Abu-hadid, M., Perez, R., Glavy, J., Zdanowicz, J., Creaven, P. J., and Pendyala, L. Altered glutathione metabolism in oxaliplatin-resistant ovarian carcinoma cells. Cancer Lett 104: 1-10, 1996.
28. El-akawi, Z. E., Zdanowicz, J., Creaven, P. J., Abu-hadid, M., Perez, R., and Pendyala, L. Induction of γ-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. Oncol. Res., in press, 1997.
29. Raghavan, D., Shipley, W. U., Garnick, M. B., Russell, P. J., and Richie, J. Biology and management of bladder cancer. New Engl. J. Med., 322: 1129-1138, 1990.
30. Ruddon, R. W. Causes of cancer. In: R. W. Ruddon (ed.), Cancer Biology, pp. 231-276. New York: Oxford University Press, 1995.
31. Reiners, J. J., Kodari, E., Cappel, R. E., and Gilbert, H. F. Assessment of the antioxidant/prooxidant status of murine skin following topical treatments with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part II: quantitation of glutathione and glutathione disulfide. Carcinogenesis (Lond.), 12: 2345-2352, 1991.
32. Hanigan, M. H., and Pilot, H. C. γ-glutamyl transpeptidase: its role in hepatocarcinogenesis. Carcinogenesis (Lond.), 6: 165-172, 1985.
33. Demi, E., and Oesterle, D. Histochemical demonstration of enhanced glutathione content in enzyme-altered islands induced by carcinogens in rat liver. Cancer Res., 40: 490-491, 1980.